Optimal patient selection for stereotactic body radiotherapy

We read with great interest the acute toxicity findings from the randomised PACE-B trial reported by Douglas Brand and colleagues comparing stereotactic body radiotherapy with either conventionally fractionated or moderately hypofractionated radiotherapy for prostate cancer. 1 Brand DH Tree AC Ostler P et al. Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings...